drugset
drugset / Trial / NCT06266832

The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma

NCT06266832 ↗

Phase 2 Recruiting 30 enrolled Sir Run Run Shaw Hospital
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy, safety and organ retention rate of short-course radiation combined with Adebrelimab and CAPEOX neoadjuvant therapy in patients with MSS/pMMR ultra low rectal adenocarcinoma.

Timeline

Start
2024-01-01
Primary completion
2025-01-01
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Adebrelimab Monoclonal antibody 20 mg/kg Intravenous
Subject Capecitabine Small molecule 1000 mg/m2 —
Subject Oxaliplatin Small molecule 130 mg/m2 Intravenous

Indications

rectum adenocarcinoma